Royal Bank of Canada
JSPR icon

Royal Bank of Canada’s Jasper Therapeutics JSPR Stock Holding History

Royal Bank of Canada’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
120
+45
+60% +$62 ﹤0.01% 7412
2025
Q4 		$0 Sell
75
-2,852
-97% -$5.72K ﹤0.01% 7392
2025
Q3 		$7K Sell
2,927
-14,881
-84% -$45.1K ﹤0.01% 6601
2025
Q2 		$99K Buy
17,808
+16,973
+2,033% +$83.6K ﹤0.01% 5613
2025
Q1 		$3K Buy
835
+603
+260% +$4.01K ﹤0.01% 6497
2024
Q4 		$5K Sell
232
-1,317
-85% -$27.4K ﹤0.01% 6537
2024
Q3 		$29K Buy
1,549
+484
+45% +$9.64K ﹤0.01% 5955
2024
Q2 		$24K Buy
1,065
+1,055
+10,550% +$25.3K ﹤0.01% 5992
2024
Q1 		$0 Sell
10
-16
-62% -$284 ﹤0.01% 7295
2023
Q4 		$0 Buy
+26
New +$175 ﹤0.01% 7349
2023
Q3 		– Sell
-26
Closed – – 7326
2023
Q2 		$0 Buy
+26
New +$386 ﹤0.01% 7445
2022
Q4 		– Sell
-256
Closed -$2K – 7473
2022
Q3 		$2K Hold
256
– – ﹤0.01% 7031
2022
Q2 		$5K Buy
+256
New +$7.29K ﹤0.01% 6648
2021
Q4 		– Sell
-20
Closed -$2K – 7786
2021
Q3 		$2K Sell
20
-189
-90% -$19.3K ﹤0.01% 7346
2021
Q2 		$21K Sell
209
-222
-52% -$22.1K ﹤0.01% 6540
2021
Q1 		$43K Buy
+431
New +$43.8K ﹤0.01% 5985
2020
Q3 		– Sell
-22
Closed -$2K – 6779
2020
Q2 		$2K Buy
+22
New +$2.15K ﹤0.01% 6284

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Royal Bank of Canada's JSPR Position: Q1 2026 in Review

Royal Bank of Canada increased its Jasper Therapeutics (JSPR) stake by 60% in Q1 2026, buying an estimated $62 and bringing the position to 120 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7412.

Royal Bank of Canada first reported a position in JSPR in Q2 2020 and has held it in 17 quarters since. The position peaked at $99K in Q2 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Royal Bank of Canada held 120 shares of Jasper Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada bought 45 Jasper Therapeutics shares in Q1 2026, an estimated $62.
  • Jasper Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7412 holding.
  • Royal Bank of Canada first reported a position in Jasper Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • Royal Bank of Canada's Jasper Therapeutics position peaked at $99K in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.